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Background: Mean platelet volume (MPV) is a platelet volume index. Classically, MPV was recognized as
a hallmark of platelet activation. Recent studies have revealed that the MPV and MPV/platelet count (PC)
ratio can predict long-termmortality in patients with ischemic cardio-vascular disease. In addition, these
indices were correlated with the pathophysiological characteristics of patients with various disorders,
including malignant tumors.
Patients and methods: We retrospectively analyzed various hematological indices of patients with
advanced non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the contribution
of platelet volume indices to survival in these patients.
Results: A total of 268 patients were enrolled in the study. The median age of the patients was 68 years
(range: 31–87 years). We compared various hematological indices between the NSCLC group and an age-
andsex-matchedcomparatorgroup.MPVwas signiﬁcantlydecreased in theNSCLCgroupcompared to the
comparator group. In contrast, the PC was signiﬁcantly increased in the NSCLC group. Consequently, the
MPV/PC ratiowasalsodecreased in theNSCLCgroup (0.397vs. 0.501). In receiveroperating characteristics
(ROC) curve analysis, theMPV/PC ratiowas associatedwith a sensitivity of 62.3% and a speciﬁcity of 74.6%
at a cutoff value of 0.408730 (area under the curve [AUC], 0.72492)]. Univariate analysis revealed that
overall survival (OS)was signiﬁcantly shorter in thegroupwith a lowMPV/PC ratio than in theother group
(median survival time [MST]: 10.3 months vs. 14.5 months, log-rank, P=0.0245). Multivariate analysis
conﬁrmed that a low MPV/PC ratio was an independent unfavorable predictive factor for OS (hazard ratio
[HR]: 1.668, 95% conﬁdence interval [CI]: 1.235–2.271, P=0.0008).
Conclusion: These data clearly demonstrate that the MPV/PC ratio was closely associated with survival in
patients with advanced NSCLC.
The A© 2013
. Introduction
Meanplatelet volume (MPV) is a platelet volume index [1]. Clas-
ically, MPV was recognized as a hallmark of platelet activation.
arger platelets are more reactive than smaller ones as they can
ore easily release chemical mediators in response to endoge-
ous or exogenous stimuli [2]. Therefore, MPV was considered
o be closely correlated with various thromboembolic disorders.
ecent studies revealed that the MPV and MPV/platelet count (PC)
atio can predict long-term mortality in patients with ischemic
ardio-vascular disease [3,4]. In addition, these indices were also
ssociated with the pathophysiological characteristics of various
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disorders, includingmalignant tumors [5–8]. Theprognostic impact
of PC in patients with non-small cell lung cancer (NSCLC) has been
extensively discussed [9–11]. Thrombocytosis was recognized as
an unfavorable predictive factor for overall survival (OS). However,
there has been no direct analysis of the survival impact of platelet
indices in patients with NSCLC. In this study, we retrospectively
analyzed patients with advanced NSCLC. The aim of this study was
to evaluate the contributionof platelet volume indices to survival in
advanced NSCLC patients. In this report, we clearly demonstrated
the survival impact of the MPV/PC ratio in patients with advanced
NSCLC.
2. Patients and methods
2.1. Data collection
Open access under CC BY-NC-SA license.The medical records of all patients with NSCLC who had under-
gone medical examination and received treatment from January
2002 toDecember 2012 at KansaiMedical University Takii Hospital
-NC-SA license.
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Table 1
Patient characteristics.
Characteristics Total patients (n=268) MVP/PC ratio≤0.48730 (n=166) MVP/PC ratio >0.408730 (n=102) P-value
Age, years 0.1231
Median (range) 68 (31–87) 67 (32–85) 69 (31–87)
Sex 0.4142
Female 76 (28.4) 50 (30.1) 26 (25.5)
Male 192 (71.6) 116 (69.9) 76 (74.5)
ECOG PS 0.7774
0–2 210 (78.4) 131 (78.9) 79 (77.5)
3 or 4 58 (21.6) 35 (21.1) 23 (22.5)
Smoking history 0.6054
Never smoked 74 (27.6) 44 (26.5) 30 (29.4)
Past or current smoker 194 (72.4) 122 (73.5) 72 (70.6)
Histological diagnosis 0.2380a
Squamous cell carcinoma 63 (23.5) 43 (25.9) 20 (19.6)
Adenocarcinoma 195 (72.8) 116 (69.9) 79 (77.5)
Others 10 (3.7) 7 (4.2) 3 (2.9)
Initial clinical stage 0.3496
IIIB 15 (5.6) 11 (6.6) 4 (3.9)
IV 253 (94.4) 155 (93.4) 98 (96.1)
Systemic chemotherapy 0.2353
None 41 (15.3) 22 (13.3) 19 (18.6)
≥1 regimen 227 (84.7) 144 (86.7) 83 (81.4)
ECOG, Eastern Cooperative Oncology Group; PS, performance status; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor; MPV/PC ratio, MPV/platelet count
ratio. Percentage is represented in parentheses.
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Xa Squamous vs. non-squamous.
Moriguchi-City, Japan) were retrospectively reviewed. Patients
ere included in this study if they had advanced NSCLC (stage IIIB
r IV), regardless of whether they had been treated with systemic
hemotherapy. The clinical disease stage was assigned on the basis
f the seventh edition of the TNM Classiﬁcation for Lung Cancer
12,13]. Data on sex, age, smoking history, clinical stage, histolog-
cal typing of cancer, Eastern Cooperative Oncology Group (ECOG)
erformance status (PS), and OS were obtained retrospectively
rom the patients’ medical records. Patients who underwent tho-
acic radiation treatment with curative intent were excluded from
he study, as were patients with large cell neuroendocrine carci-
oma. The age- and sex-matched comparator group was randomly
elected from among patients with chronic obstructive pulmonary
isease (COPD) or bronchial asthma who had undergone medi-
al examination in our hospital during the aforementioned period.
he case–control ratio was deﬁned as 2:1. Patients with a history
f malignant tumor were excluded from the comparator group.
atients with levels of C-reactive protein (CRP) higher than the
nstitutional normal upper limit were also excluded from the
omparator group, as were patients with an active infection or
nﬂammation. Laboratory data, including the complete blood count
CBC), were obtained from medical records. The results preced-
ng the initial histological or cytological diagnosis of NSCLC were
onsidered.
This retrospective study was performed in accordance with
he Declaration of Helsinki and was approved by the institutional
thics review board (the clinical research board of Kansai Medi-
al University Takii Hospital, institutional ID: 24-33, UMIN–CTR:
MIN000010287).
.2. Biochemical analysis of blood samplesCBC and various platelet volume indices were measured using
thylenediaminetetraacetic acid (EDTA)-treated blood. An auto-
ated blood cell counter was used for these analyses (Sysmex
E-2100, Kobe, Japan). The CRP concentration was measuredusing an automatic analyzer (Beckman Coulter AU5400, Miami,
FL).
2.3. Statistical analysis
Statistically signiﬁcant differences between the groups were
compared using the chi-square or Student’s t test. Receiver oper-
ating characteristics (ROC) curve analysis was used to estimate an
optimal cutoff value for the MPV/PC ratio. OS was deﬁned as the
time from initial diagnosis to the time of death from any cause or
the date the patientwas last known to be alive. Univariate andmul-
tivariate analyses of OS were performed using the Kaplan–Meier
product-limit method with the log-rank test and the Cox propor-
tional hazardsmodel, respectively. The 95% conﬁdence interval (CI)
for the survival rate was calculated using Greenwood’s method.
To calculate the 95% CI of the median survival time (MST), the
Brookmeyer and Crowley method was used. All statistical analyses
were conducted using the JMP (version 9.0.2) software program for
Windows (SAS Institute Inc, Cary, NC). All statistical testswere two-
sided, and P<0.05 was considered to be statistically signiﬁcant.
3. Results
3.1. Patient characteristics
A total of 268 patients with NSCLC were enrolled in this study.
The characteristics of these 268patients are summarized in Table 1.
All the patients were Asian (Japanese, Korean, or Chinese), their
median age was 68 years (range: 31–87 years), and they included
76 women and 192 men. One hundred and ninety-four patients
had a history of smoking whereas the remaining 74 patients had
never smoked. The numbers of patients with squamous cell carci-
noma, adenocarcinoma, and other carcinomas were 63, 195, and
10, respectively. The ECOG PS was 0–2 in 210 patients and 3–4
in 58 patients. Fifteen patients had stage IIIb disease, whereas
253 patients had stage IV disease. Two hundred and twenty-seven
g Cancer 83 (2014) 97–101 99
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Table 2
Patient characteristics.
Characteristics NSCLC patients
(n=268)
Comparator
group (n=134)
P value
Age, years 0.8445
Median (range) 68 (31–87) 68 (33–85)
Sex 1.0000
Female 76 38
Male 192 96
Smoking history 0.0101*
Never smoked 74 54
Past or current smoker 194 80
PC, 104/L 27.2±8.7 21.7±5.5 <0.0001*
MPV, ﬂ 9.59±0.80 10.16±0.82 <0.0001*
PDW, ﬂ 10.74±1.53 11.70±1.67 <0.0001*
P-LCR, % 21.42±6.45 25.86±6.62 <0.0001*
MPV/PC ratio, ﬂ 10−4L−1 0.397±0.160 0.501±0.144 <0.0001*
MCV, ﬂ 91.8±5.4 93.1±4.3 0.0139*
MCHC, g/dL 32.9±0.9 33.2±1.0 0.0034*
RDW, ﬂ 45.4±4.5 45.1±4.5 0.5817
WBC, 102/L 85.6±41.9 64.8±19.7 <0.0001*
CRP, mg/dL 2.761±4.296 0.088±0.069 <0.0001*
Data arepresented asmean± standarddeviation.NSCLC, non-small cell lung cancer;
PC, platelet count; MPV, mean platelet volume; PDW, platelet distribution width;
P-LCR, platelet large cell ratio; MPV/PC ratio, MPV/platelet count ratio; MCHC, mean
F
aN. Inagaki et al. / Lun
atients had received at least 1 regimen of systemic chemother-
py, whereas 41 patients had received best supportive care alone.
peciﬁcally, a history of epidermal growth factor receptor-tyrosine
inase inhibitor (EGFR-TKI) treatmentwas reported in107patients,
hereas the remaining 161 patients had not received EGFR-TKI
reatment.
.2. Comparison of hematological indices between NSCLC
atients and the control group
To evaluate the hematological indices of patients with NSCLC,
comparator group of 134 age- and sex-matched patients was
andomly selected from among patients with COPD or bronchial
sthma. The data from the 2 groups are summarized in Table 2.
here were no signiﬁcant differences in age and sex between the
groups. The MPV, platelet distribution width (PDW), and platelet
arge cell ratio (P-LCR) were signiﬁcantly lower in the patients with
SCLC than in the comparator group. In contrast, the PC, mean
orpuscular volume (MCV),mean corpuscular hemoglobin concen-
ration (MCHC), white blood cell count WBC), and CRP level were
igniﬁcantly elevated in the patients with NSCLC than in the com-
arator group. Red blood cell distribution width (RDW) did not
iffer signiﬁcantly between the groups. Interestingly, the MPV/PC
atio was also signiﬁcantly decreased in the patients with NSCLC.
e calculated the cutoff value for theMPV/PC ratio usingROCcurve
nalysis. A cutoff value of 0.408730 was found to be an identiﬁer
alue for patients with advanced NSCLC, with a sensitivity of 74.6%
nd speciﬁcity of 74.6% (area under the curve [AUC], 0.72492).
.3. Comparisons according to the MPV/PC ratio
We divided the patients with NSCLC into 2 groups according
o the cutoff value for the MPV/PC ratio of 0.408730. The charac-
eristics of the 2 groups are summarized in Table 1. There were
o signiﬁcant differences in age, sex, PS, clinical stage, smoking
istory, or histological typing proportions between the 2 groups.
e also reanalyzed the MPV, PC, and MPV/PC ratio in 3 groups:
SCLC patients with a low MPV/PC ratio; those with a high MPV/PC
atio; and the comparator group (Fig. 1). MPV was signiﬁcantly
ecreased in the NSCLC patients with low MPV/PC ratio compared
o the comparator group (9.31±0.61 vs. 10.16±0.82, P<0.0001,
ig. 1. Dot plot analyses of the mean platelet volume (MPV) and platelet count (PC). Dot
nd the control group.corpuscular hemoglobin concentration; RDW, red blood cell distribution width;
WBC, white blood cell; CRP, C-reactive protein.
* P<0.05.
Fig. 1A). However, there was no signiﬁcant difference in MPV val-
ues between the NSCLC patients with a high MPV/PC ratio and the
comparator group (10.00±0.87 vs. 10.16±0.82, P=0.2191). In con-
trast, the PC was signiﬁcantly increased in NSCLC patients with a
low MPV/PC ratio compared to the comparator group (32.1±7.1
vs. 21.7±5.5, P<0.0001, Fig. 1B). However, the PC was also slightly
decreased in NSCLC patients with a low MPV/PC ratio compared
to the comparator group (19.7±3.8 vs. 21.7±5.5, P=0.0013).
These ﬁndings suggest that NSCLC patients with a high MPV/PC
ratio and the comparator group share similar characteristics in
terms of volume and number of platelets. However, the NSCLC
patients with a low MPV/PC ratio were an independent group, not
only from the comparator group but also from the group with a
plot analyses of the MPV (A) and PC (B) in the different groups of NSCLC patients
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Table 3
Univariate analysis of overall survival.
Variable MST (months) P value
MPV/PC ratio, low vs. high 10.3 vs. 14.5 0.0245*
Female vs. male 15.8 vs. 9.6 0.0018*
Never-smoker vs. smoker 16.3 vs. 10.3 0.0028*
Age, <70 years vs. ≥75 years 11.8 vs. 10.0 0.5922
ECOG PS 0/1/2 vs. 3/4 13.4 vs. 3.8 <0.0001*
Non-sq vs. sq 12.5 vs. 8.6 0.0003*
Stage IIIb vs. IV 17.8 vs. 10.6 0.2390
MST, median survival time; PS, performance status; Sq, squamous cell carcinoma;
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Table 4
Multivariate analysis of overall survival.
Covariate HR 95% CI P value
MPV/PC ratio, low vs. high 1.668 1.235–2.271 0.0008*
Female vs. male 0.505 0.331–0.759 0.0009*
Never-smoker vs. smoker 1.018 0.673–1.522 0.9325
Age, <75 years vs. ≥75 years 0.853 0.611–1.214 0.3697
PS 0/1/2 vs. 3/4 0.305 0.215–0.449 <0.0001*
Non-Sq vs. Sq 0.578 0.411–0.824 0.0027*
Stage IIIB vs. IV 0.536 0.271–0.954 0.0330*PV/PC ratio,MPV/platelet count ratio; ECOG,EasternCooperativeOncologyGroup;
S, performance status.
* P<0.05.
igh MPV/PC ratio, with respect to the kinetics of the circulating
latelets.
.4. Univariate analyses for OS
We conducted a series of survival analyses on June 1, 2013. At
hat time, 203 patients had died, 46 patientswere lost to follow-up,
nd 19 patients were still alive. Consequently, the censoring rate
as estimated at 24.3%. In univariate analyses, OS was signiﬁcantly
ncreased in patients who were women (P=0.0018); those had
ever smoked (P=0.0028); those with a PS of 0, 1, or 2 (P<0.0001);
nd those with non-squamous cell carcinoma (P=0.0003). How-
ver, clinical stage (P=0.2390) and patient age (P=0.5922) were
ot statistically signiﬁcant (Table 3). We also analyzed the con-
ribution of the MPV/PC ratio to OS. The MSTs were 10.3 months
95% CI: 7.7–13.1) and 14.5 months (95% CI: 10.0–18.6) for patients
ith low and high MPV/PC ratios, respectively (Fig. 2). The 1-year
urvival rates were 43.8% (95% CI: 35.9–51.7) and 55.8% (95% CI:
4.5–66.1) for thosewith low and highMPV/PC ratios, respectively.
nunivariate analysis,OSwas signiﬁcantlydecreased in thepatients
ith a low MPV/PC ratio (P=0.0245). We subsequently conducted
multivariate analysis to evaluate the independent survival impact
f the covariates.
.5. Multivariate analysis for OSMultivariate analysis clearly revealed that a low MPV/PC ratio
as an independent unfavorable prognostic factor for OS (hazard
atio [HR], 1.668, 95%CI: 1.235–2.271, P=0.0008). In contrast, being
emale (P=0.0009); having a PS of 0, 1, or 2 (P<0.0001); having
ig. 2. Kaplan–Meier curves for overall survival (OS) of the patients according to the
PV/PC ratio. The median survival times (MSTs) for the group with a low MPV/PC
atio and the group with a high MPV/PC ratio were 10.3 and 14.5 months, respec-
ively (log-rank, P=0.0245).MST, median survival time; PS, performance status; Sq, squamous cell carcinoma;
G, grade; ns, not signiﬁcant.
* P<0.05.
non–squamous cell carcinoma (P=0.0027); and having stage IIIb
disease (P=0.0330) were independent favorable prognostic factors
(Table4). Beingyounger than70years (P=0.3697)washowevernot
a signiﬁcant factor. In contrast to the results of univariate analysis,
no signiﬁcant difference in OS was observed between patients with
andwithout a history of smoking (P=0.9325). These results suggest
the presence of a confounding factor that that affects the impact of
a smoking history.
4. Discussion
At present, evaluation of the MPV is attracting a great deal of
interest. Several reports have shown that an elevation of MPV is
closely associated with the severity and prognosis of cerebro- and
cardio-vascular disorders [3,4,14,15]. Khode et al. showed thatMPV
was signiﬁcantly higher in patients with acute myocardial infarc-
tion than in healthy controls [16]. Furthermore, the MPV/PC ratio
was preferentially proposed as a predictor of long-term mortal-
ity after non-ST elevation myocardial infarction [3]. In addition to
ischemic cardiovascular disorders, the elevation of MPV has also
been reported in malignant tumors. Osada et al. showed that the
MPV was higher in patients with gastric cancer than in control
patients [7]. They also demonstrated upregulation of P-selectin, a
well-knownmarkerofplatelet activation, on the surfaceofplatelets
in the gastric cancer patients. Furthermore, Cho et al. demonstrated
that the MPV and MPV/PC ratio were elevated in patients with
hepatocellular carcinoma (HCC) [6]. However, counterevidence has
also been reported. Mutlu et al. analyzed the MPV in patients with
various cancers at the time of diagnosis and at the time of any
thrombotic event [17]. They did not detect MPV elevation at the
time of diagnosis. Moreover, they found a signiﬁcant reduction in
MPV values at the time of thrombotic events compared to those at
diagnosis. In addition, Aksoy et al. revealed that the MPV was sig-
niﬁcantly decreased in various cancer patients with metastasis to
the bone marrow compared to control patients [18]. These ﬁndings
strongly support our own. We revealed a signiﬁcant reduction in
the MPV and MPV/PC ratio in patients with advanced NSCLC. This is
the ﬁrst report presenting a reduction in theMPV andMPV/PC ratio
in patients with NSCLC. We found one previous report assessing
platelet indices for patients with lung cancer [19]. However, they
did not show signiﬁcant reduction in theMPVvalues in the patients
with lung cancer. It is possible that they could not demonstrate dif-
ferences in platelet indices between patients with lung cancer and
healthy controls because their study population was smaller and
heterogeneous.
However, this phenomenon in NSCLC is contradictory to that
seen in gastric cancer and HCC [5–8]. One possible explanation
could be that the circulating platelet count is restricted by throm-
bopoiesis in the bone marrow and is therefore inversely correlated
to MPV [1,20]. Strict physiological controls play an important role
in the maintenance of homeostasis. As the lung is a vital organ,
an advanced tumor derived from it could easily evoke a status
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f chronic inﬂammation due to various complications, includ-
ng obstructive pneumonia and malignant serositis, leading to an
pregulation of various proinﬂammatory cytokines such as TNF-
, IL-1, and IL-6 [21–23]. These cytokines induce acceleration of
hrombopoiesis in the bone marrow, leading to an elevation in
he circulating platelet count [24,25]. In addition, lung cancer cell-
erived micro-particles bearing P-selectin and tissue factor also
ccelerate the activation of platelets, resulting in disseminated
icro-thrombosis [26]. As larger platelets are more reactive in
esponse to stimuli, selective consumption of larger plateletsmight
ccur. Consequently, the MPV of circulating platelets would be
ecreased. Micro- and macro-thromboembolic events are one of
he major complications for patients with advanced NSCLC and can
e fatal [27–29]. Therefore, this may be a possible explanation for
he poor prognosis of patients with a low MPV/PC ratio.
The MPV and PC were also signiﬁcant prognostic factors for OS
n univariate analyses (P=−0.0270 and P=0.0124, respectively).
owever, multivariate analysis did not indicate the superiority of
hemagainst theMPV/PC ratiowhenconsidered independently (HR
f a low MPV/PC ratio: 1.668 [P=0.0008], HR of a low MPV: 1.381
P=0.0121], and HR of a high PC: 1.380 [P=0.0114]). Therefore, we
oncluded that the MPV/PC ratio was a more reliable and accurate
iomarker than the MPV or PC alone.
Despite the retrospective nature and small size of the present
tudy, our results clearly demonstrated that a low MPV/PC ratio at
nitial diagnosis was an independent unfavorable prognostic fac-
or for patients with advanced NSCLC. Further investigation should
larify the etiology by which the amount and volume of circulating
latelets modulate mortality in patients with NSCLC.
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